Journal of Cancer Therapy

Vol.7 No.4(2016), Paper ID 65793, 10 pages

DOI:10.4236/jct.2016.74029

 

Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival

 

Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho

 

Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Medical Oncology, Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, Brazil
Medical Oncology, Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, Brazil
Sao Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clínicas, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil

 

Copyright © 2016 Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Alencar, R. , Kikuchi, L. , Tani, C. , Chagas, A. , Camargo, C. , Pfiffer, T. , Hoff, P. and Carrilho, F. (2016) Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. Journal of Cancer Therapy, 7, 275-284. doi: 10.4236/jct.2016.74029.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.